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Abstract
Background: Neuroinflammation is an important secondary mechanism that is a key mediator of the long-term
consequences of neuronal injury that occur in traumatic brain injury (TBI). Microglia are highly plastic cells with dual
roles in neuronal injury and recovery. Recent studies suggest that the chemokine fractalkine (CX3CL1, FKN) mediates
neural/microglial interactions via its sole receptor CX3CR1. CX3CL1/CX3CR1 signaling modulates microglia activation,
and depending upon the type and time of injury, either protects or exacerbates neurological diseases.
Methods: In this study, mice deficient in CX3CR1 were subjected to mild controlled cortical impact injury (CCI), a
model of TBI. We evaluated the effects of genetic deletion of CX3CR1 on histopathology, cell death/survival, microglia
activation, and cognitive function for 30 days post-injury.
Results: During the acute post-injury period (24 h–15 days), motor deficits, cell death, and neuronal cell loss were more
profound in injured wild-type than in CX3CR1−/− mice. In contrast, during the chronic period of 30 days post-TBI, injured
CX3CR1−/− mice exhibited greater cognitive dysfunction and increased neuronal death than wild-type mice.
The protective and deleterious effects of CX3CR1 were associated with changes in microglia phenotypes; during the
acute phase CX3CR1−/− mice showed a predominant anti-inflammatory M2 microglial response, with increased
expression of Ym1, CD206, and TGFβ. In contrast, increased M1 phenotypic microglia markers, Marco, and CD68 were
predominant at 30 days post-TBI.
Conclusion: Collectively, these novel data demonstrate a time-dependent role for CX3CL1/CX3CR1 signaling after TBI
and suggest that the acute and chronic responses to mild TBI are modulated in part by distinct microglia phenotypes.
Keywords: CX3CR1, TBI, Microglia, Cognitive function, Cytokines

Background
Traumatic brain injury (TBI) is a serious public health
problem in the United States. Mild TBI is rarely recognized in a timely manner because symptoms often do
not manifest for some time after the injury. However,
the consequences of mild TBI can be long lasting. The
pathophysiology of TBI is complex, in part because multiple pathways are involved in the primary and secondary
injuries that result from the insult.
A consensus based on recent evidence considers neuroinflammation as an important secondary mechanism
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that plays a role in delaying injury after TBI [1–3]. Dysregulated and uncontrolled microglial activation may be a
key component of chronic neuroinflammatory processes.
Recent studies suggest that the chemokine fractalkine
(CX3CL1, FKN) mediates neural/microglial interactions
via its sole receptor CX3CR1. Indeed, deleting CX3CR1
[4] exacerbates microglial neurotoxicity induced by systemic inflammation in rodent models of Parkinson’s disease and amyotrophic lateral sclerosis [5]. In addition,
CX3CR1−/− microglia exacerbate cell-autonomous microglial neurotoxicity induced by lipopolysaccharide (LPS),
suggesting that fractalkine signaling is important for limiting microglia toxicity [5, 6]. CX3CL1 also protects against
excitotoxicity through the activation of the ERK1/2 and
PI3K/Akt pathways [7, 8]. However, the role of FKN/
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CX3CR1 signaling in neurodegenerative disease is an intricate and highly debated research topic that is becoming
even more complicated as new studies reveal seemingly
discordant results. It appears that FKN/CX3CR1 signaling
plays a direct role in neurodegeneration and/or neuroprotection depending upon the CNS insult. Both beneficial
and detrimental effects of CX3CR1 deficiency are associated with microglia activation [9–11]. Data from some
models of chronic neuronal injury suggest that CX3CR1 is
protective because the absence of this receptor increases
microglia activity and is associated with less favorable outcome [8, 12–16]. For instance, in a model of Alzheimer’s
disease (AD), CX3CR1-deficient microglia from mice
overexpressing hTau have increased hyperphosphorylated
tau and more toxicity, as has been observed in other
animal’s disease models [5, 17–20]. On the other hand, in
3x-Tg AD mice, which reproduces both Aβ and tau pathologies, deleting CX3CR1 prevents neuronal loss and
microglial migration without affecting amyloid deposition
[21]. Finally, other reports indicate that CX3CR1 deficiency attenuates amyloid deposition in AD mouse models
characterized by extensive plaque deposition [18, 22].
The complex CX3CL1/CX3CR1 signaling pathway is
further complicated by its functional role in acute injuries. Results from some acute injury models suggest that
CX3CR1 is detrimental because its absence is associated
with a favorable outcome. For instance, in a model of
cerebral ischemia and spinal cord injury, CX3CR1−/− mice
showed neuroprotection and improved functional recovery [23–26]. These observations suggest that CX3CR1
may play different roles in neuronal injury depending on
the type of injury and on the post-injury time point
assessed (chronic vs acute). CX3CL1 levels increase in the
cerebrospinal fluid and in the brain of patients with head
trauma, and increased CX3CL1/CX3CR1 is associated
with better clinical outcome [27, 28]. However, few preclinical studies of TBI focus on the CX3CL1/CX3CR1 system. Determining a role for CX3CL1/CX3CR1 signaling
in outcomes after mild TBI during the acute and chronic
phase is a goal of the present study.
We now know that the microglia assume diverse phenotypes in response to specific microenvironmental signals. Although there is a spectrum of different microglial
types, there are two major microglia phenotypes characterized by a molecular signature of gene expression: the
“classical” inflammatory state (M1) and the “alternative”
activation state (M2). M1 microglia are generally considered pro-inflammatory whereas, M2 microglia are generally anti-inflammatory [29–34]. In the healthy young
brain, M1 and M2 microglia exist in a state of dynamic
equilibrium. Following an injury, there is a shift into an
M1 phenotype that exacerbates tissue injury or into an
M2 phenotype that promotes CNS repair, depending on
the local signals in the lesion’s microenvironment [35].
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In this study, we demonstrate that lack of CX3CL1/
CX3CR1 signaling in the brain leads to delayed neuronal damage and neurologic and cognitive impairment
after TBI that is associated with a switch in microglia
phenotype. Our data suggest a time-dependent effect
of CX3CR1 on modulating brain injury and suggests
a potential unique therapeutic window for treating
TBI neuroinflammation.

Materials and methods
Animals

All experiments were conducted in accordance with the
National Institute of Health Guide on Care and Use of Laboratory Animals and were approved by the Institutional
Animal Care and Use Committee of the University of
Washington. CX3CR1−/− (CX3CR1 GFP/GFP) mice were
obtained from The Jackson Laboratory (Bar Harbor,
Maine) and a colony established at the University of
Washington. A total of 180 3-month-old male CX3CR1−/−
and littermate CX3CR1+/+ (wild-type) mice were used in
these experiments. Mice were group-housed in environmentally controlled conditions (12:12 h light-to-dark cycle
at 21 ± 1 °C) and provided with food and water ad libitum.
After surgery, animals were single-housed.
Traumatic brain injury

Adult mice were anesthetized with isoflurane (induced
at 4 %, maintained at 1.25–1.5 %) and placed in a stereotaxic frame equipped with a heating pad to maintain
body temperature. A midline incision was made, fascia
removed, and a 5-mm diameter craniotomy was made
over the left parietal cortex between the lambda and
bregma. The bone flap was removed and the integrity of
the underlying dura assessed. TBI was induced using a
controlled cortical impact (CCI) device (Leica Impact
One, Richmond, IL, USA) equipped with an electrically
driven 3-mm diameter metal piston controlled by a linear velocity displacement transducer. Impact velocity
was set at 5.0 m/s, with a dwell time of 100 ms, and a
depth of 0.5 mm from the dura. Previous studies have
reported that these parameters produce a mild injury
[36, 37]. A 5-mm disk created from a polystyrene weighing boat was glued to the skull over the craniotomy, and
the incision closed with sutures. Mice were kept on a
heating pad and allowed to recover until ambulatory before being returned to their home cages. Sham (uninjured control) animals received identical anesthesia and
craniotomy but were not subjected to CCI brain injury.
Tissue collection and processing

For immunohistochemistry studies, animals were anesthetized with isofluorane and transcardially perfused with
ice-cold phosphate-buffered saline (PBS), followed by 4 %
paraformaldehyde in PBS. The brains were postfixed in
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4 % paraformaldehyde for 24 h, after which they were
transferred to a 30 % sucrose in PBS for at least 16 h
at 4 °C. Coronal sections of the left hemisphere were made
at 40 μm using a cryostat (Leica CM1950) and stored in
cryoprotectant at 4 °C. Animals used for protein assessment were euthanatized by rapid decapitation.
Brain regions of interest were dissected and rapidly
frozen in liquid nitrogen before storage at −80 °C.
Subsequently, both the hippocampi and the sections
of cortex were homogenized using an electric tissue
homogenizer in 1:10 weight-to-volume ratio of icecold RIPA buffer (Millipore; Billerica, MA, USA) containing protease inhibitors and EDTA (Pierce; Rockford, IL,
USA). Following homogenization, sample lysates were
centrifuged at 10,000×g at 4 °C for 15 min and the supernatant collected.
Biochemical endpoints
Enzyme-linked immunosorbent assay (ELISA)

The total protein in each sample was determined using
the bicinchoninc acid method (BCA; Pierce Biotechnology, Inc.).
Analysis of gene expression by qRT-PCR

Dissected cortex tissues from adult male mice were
stored at −80 °C, and total RNA was isolated with RNeasy
Lipid Tissue Mini Kit (QIAGEN, catalog # 74804) with oncolumn DNase treatment (QIAGEN, catalog # 79254) according to the manufacturer’s protocol. RNA quantity and
quality were determined using A260/A280 readings by a
NanoDrop (ThermoScientific) spectrophotometer. Reverse
transcription (RT) was performed using High Capacity
cDNA Reverse Transcription Kit Assay (Applied Biosystems, catalog # 4368814) following the manufacturer’s
protocol. “No template” and “no RT” controls were included in all assays.
RT-PCR was performed using the TaqMan Gene Expression Assay (Applied Biosystems, catalog # 4331182)
according to the manufacturer’s instructions on a 7300
Real Time PCR System (Applied Biosystems). The following TaqMan probes were used: Il-1β (Mm00434228_m1),
Cd86 (Mm0444543_m1), Fcgr1 (Mm0438874_m1),
Tgfb1 (Mm01178820_m1), Arg1 (Mm00475988_m1),
Nos2 (iNOS), (Mm00440502_m1), and 18S (Mm03928
990_g1). Relative gene expression was calculated by 2−ΔΔCT
method.
Immunohistochemistry

Except where indicated, staining was done on 40-μm freefloating sections of a one-in-six series through the entire
hippocampus and cortex. Tissue was blocked in 10 % normal serum from the species in which the secondary antibody was raised, with the addition of 0.1 % Triton X-100.
Primary antibodies were diluted in 3 % normal serum with
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0.1 % Triton X-100, and tissue incubated overnight at
4 °C. Biotinylated secondary antibodies were diluted
in 3 % normal serum with 0.1 % Triton X-100 and
were incubated for 2 h at room temperature. Enzyme
detection was done using avidin-biotin substrate
(ABC kit, Vector Laboratories, Burlingame, CA, USA)
followed by color development in diaminobenzidine solution (Sigma-Aldrich, St. Louis, MO, USA). Antibodies and
dilutions were as follows: rat CD11b (Serotec, Raleigh, NC,
USA; 1:500); mouse CD68 (Serotec; 1:200); rabbit YM1
(Stem cell technology, Vancouver, BC, Canada; 1:400);
rat Marco (Serotec; 1:500); mouse NeuN (Millipore,
Temecula, CA, USA; 1:1000). After incubation for
24–48 h with appropriate primary and biotinylated
secondary antibodies, tissue was treated with Vectastain
ABC reagent (Vector Labs) and visualized with DAB reaction (Sigma-Aldrich). Controls included omitting primary or
secondary antibodies.
Fluoro-Jade B staining

Fluoro-Jade B staining was performed according to
Kubova et al. [38]. Briefly, 40-μm coronal free-floating
sections were washed three times for 10 min with 0.1 M
phosphate buffer saline (PBS), mounted on glass slides,
and dried overnight at 37 °C. The sections were then incubated in chloroform-ethanol (1:1) for 1 h. Next, tissue
was rehydrated in absolute ethanol (3 min), 70 % ethanol
(2 min), distilled water (2 min), incubated in 0.06 %
KMnO4 for 15 min, rinsed in distilled water (2 min), and
incubated for 30 min in a solution containing 0.001 %
Fluoro-Jade B (Histo-Chem, Jefferson, AR, USA) and
0.1 % acetic acid. Sections were then rinsed in distilled
water, dehydrated in a series of xylene and coverslipped.
Stereological analysis

All cell counts were obtained using the Optical Fractionator method of unbiased stereological counting techniques [39]. An Olympus BX-51 microscope and the
Stereo Investigator software (MBF Bioscience, Colchester,
VT, USA) were used to obtain cell counts on sections systematically sampled throughout the entire hippocampus
and parietal cortex as described earlier [40]. Neuroanatomical borders of the hilus of the dentate gyrus were outlined, and counting was confined to these areas. The
virtual grid (175 × 175) and counting frame (100 × 100)
were optimized to count at least 200 cells per animal with
error coefficients less than 0.07. Outlines of the anatomical structures were made using a 10×/0.45 objective, and
cell quantification was done with a 60×/1.40 objective.
Isolation of mononuclear cells and flow cytometry

Perfused brains were dissected from mice 15 and 30 days
post-TBI, mononuclear cells separated over discontinuous 70/30 % percoll gradients as previously described
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[41, 42], and cellular pellets resuspended in cell staining
buffer (Biolegend, San Diego, CA, USA). Blood for single
stained controls was collected from the submandibular
vein and RBCs depleted by hypotonic lysis and washed
in staining buffer. Isolated cells were incubated on ice
for 5 min with anti-mouse CD16/CD32 (clone 2.4G2;
BD Pharmingen) to block Fc fragment receptor (FcR)s
and then incubated on ice for 30 min with a mix of
fluorochrome-conjugated anti-mouse Abs; CD45-APC-Cy7
or APC (Clone 30-F11, BD Pharmingen), CD11b-APC or
PerCP-Cy5.5 (Clone M1/70), CD11c-PeCy7 (Clone N418,
eBioscience), Ly6G-PE (Clone 1A8, Biolegend), and I-A/IE-PerCP or Pacific Blue (Mouse MHC-II Clone M5/
114.15.2). After washes, cells were resuspended in 2 % paraformaldehyde and analyzed in a LSR-II (BD Biosciences,
Franklin Lakes, NJ, USA). To quantify the proportion of
resident and infiltrating myeloid cells undergoing cell proliferation, CNS mononuclear cells were stained first with
cell surface markers, fixed with 4 % PFA for 30 min and
then incubated at RT for 10 min in permeabilization buffer
(eBioscience). Cells were then stained with Ki67-V450
(Clone B56) in permeabilization buffer for 20 min, washed,
resuspended in 2 % PFA, and acquired on an LSR-II [43].

injured and sham-operated animals, and baseline composite neuromotor scores were calculated from values obtained 24 h prior to injury.

Behavioral analysis
Composite neuroscore

Rota-rod

Evaluation of neuromotor impairment following CCI
was performed by using a 28-point composite neuroscore. In brief, mice were evaluated by an investigator
blinded to the injury status (sham, TBI) of the animal.
Scoring for each animal ranged from 0 (severely impaired) to 4 (normal strength or function) for each of
the following modalities: (1) left and (2) right forelimb
flexion during suspension by the tail; (3) left and (4)
right hind limb flexion with the forelimbs remaining on
a flat surface as the hind limbs are lifted by the tail; (5)
ability to resist lateral pulsation to the left and (6) right;
and (7) ability to stand on an inclined plane in the left,
(8) right, and (9) vertical position. In addition, the ability
of mice to stand on an inclined plane for at least 5 s in
each of three directions (facing up, left, and right) was
determined. The angle was increased in 2.5° increments
starting at 40°; the maximal angle was noted and compared with pre-injury (baseline) values. A score was then
assigned based on the decrease from baseline angle in
degrees, where 4 = 0° change, 3 = 2.5° change, 2 = 5°
change, 1 = 7.5° change, and 0 = 10° change or greater.
Each of the three directions was scored separately, after
which a mean was calculated, giving a maximum score
of 4 for the inclined plane. The scores for (7), (8), and
(9) were averaged, and a composite neurological motor
score (0–28) was calculated by summation of individual
test scores. Neuromotor function was assessed in both

Open-field and elevated plus maze

The open-field and elevated plus maze were used to determine general activity levels and to measure anxietylike behavior. Animals were monitored under moderate
lighting for 15 min in a 40-cm2 open field using video
tracking software (ANY-Maze, Stoelting, IL, USA). General activity was evaluated by determining the total of
distance traveled. Anxiety-like behavior was assessed
based on the pattern of exploration in the open field
(center versus periphery). Anxiety-like behavior was also
assessed using the elevated plus maze. Our elevated plus
maze consists of two well-lit open arms (35 cm) facing
each other and two enclosed arms (30.5 cm) also facing
each other. Each arm is attached to a common center
platform (4.5 cm2), and the entire apparatus was elevated 40 cm off the floor. The mice were placed in the
center platform and allowed to explore for 5 min. Video
tracking software (ANY-Maze) measured movement and
time spent in each section.

Mice were tested for overall balance, motor coordination, and motor learning on an accelerating rota-rod
apparatus (Ugo Basile, Italy). The center rotor is a 3-cm
diameter cylinder, and rotation started at 4 rpm and accelerated to 40 rpm within a 5-min period. Mice were
tested for the time spent on the rotor during each of
four trials with a 30-min inter-trial interval, and time to
fall off the rotor was the outcome measured.
Morris water maze

The Morris hidden platform water maze (MWM) consisted of a circular pool (1.38 m diameter) filled with
room temperature water containing non-toxic opaque
paint with an escape platform (10 cm diameter) hidden
3 cm beneath the surface. Each mouse was placed in the
pool in a pseudorandom order and given 60 s to locate
the escape platform. When the mouse found the platform, or if it failed to find the platform within 60 s, it
was placed on the platform and left for 30 s. Each mouse
was given four trials per day for 7 days with 1-h intertrial interval between trials. Sessions were recorded, and
the time to find the platform (escape latency), the total
distance traveled, and swim speed were determined by
video tracking software (ANY-Maze). After each session,
mice were towel-dried and placed in a cage on a heating
pad until dry, after which they were returned to their
home cage. On day 8 post-training, all mice were subjected to one probe trial in which the platform was
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removed and each animal had 60 s to search the pool
for the platform.
Statistical analysis

Statistical analyses comparing two genotypes, two manipulations (sham and TBI), and two time points (15
and 30 days post-injury) were done using a one-way analysis of variance (ANOVA) or two-way ANOVA with
post hoc multiple comparison analysis (Tukey-Kramer
or Bonferroni post hoc test). Repeated measures ANOVA
followed by Bonferroni post hoc comparisons were used
to analyze rota-rod data. Flow cytometry data are presented as number of cells or percentage of specific cell
populations. Differences between groups were analyzed
using ANOVA or an unpaired t test with GraphPad Prism
software (San Diego, CA, USA). P values are shown in the
data (*) when P < 0.05. Statistical analysis was done in the
GraphPad Prism software.

Results
Mild TBI impairs neuromotor function

Prior to surgery, there were no differences in composite
neuroscores between WT and CX3CR1−/− mice. The
brain-injured WT mice had lower composite neuroscores
at 24 h, 7, and 15 days post-surgery than sham WT mice
(Fig. 1). By 30 days post-surgery, composite neuroscores
for the brain-injured WT and sham WT mice did not differ, indicating recovery of neuromotor function. Composite neuroscores for the brain-injured WT mice were
significantly lower than those of brain-injured CX3CR1−/−
mice at 24 h post-injury but not at 7 or 15 days postinjury. Composite neuroscores for the brain-injured
CX3CR1−/− mice did not differ from those of sham
CX3CR1−/− mice at any time point, indicating that
CX3CR1 deficiency is neuroprotective.
Mild TBI does not affect spontaneous locomotor activity
or cause excessive anxiety but impairs motor learning
and cognitive function

Separate groups of animals (n = 10/group) were evaluated in open-field, elevated plus maze, rota-rod, and
Morris water maze 30 days post-TBI.
To examine spontaneous locomotor activity in response to a novel environment, all mice were tested in
the open-field behavioral task. The open-field task monitors activity in a brightly lit, novel environment. Spontaneous locomotor activity was assessed as the total
amount of distance traveled in the chamber. In addition,
anxiety levels can be measured in the open-field task
through assessment of the distances traveled in the center versus perimeter of the chamber. This task exploits
the natural tendency of mice to avoid open areas.
In the open-field task, there were no genotype differences in distance traveled. WT mice subjected to TBI

Fig. 1 Composite neuroscore (mean ± SEM). Evaluation of neuromotor
function and recovery over a 30-day period. At 24 h post-TBI, injured
WT mice (n = 3) demonstrated a significant decline in neuromotor
function compared with sham WT (n = 4) and CX3CR1−/− injured
mice (n = 4; two-way ANOVA, F (1, 9) **p = 0.001; **p = 0.001). At 7 days
post-TBI, injured WT mice (n = 5) continued to demonstrate significant
impairment than sham WT mice (n = 5; two-way ANOVA,
F (1, 15) *p = 0.01). Injured CX3CR1−/− mice (n = 4) were not different
from the injured WT mice (p > 0.05). A significant impairment in motor
function performance was still present at 15 days post-injury in injured
WT mice (n = 8) compared to sham WT mice (n = 8; two-way ANOVA,
F (1, 15) **p = 0.001;). Injured CX3CR1−/− mice (n = 8) were not different
from the injured WT mice (n = 8; p > 0.05). All injured mice (n = 5)
recovered similarly at 30 days post-TBI. White bar = CX3CR1 sham WT.
Green bar = CX3CR1 sham KO. Red Bar = CX3CR1 WT-TBI. Blue
bar = CX3CR1 KO-TBI

spent less time in the perimeter zone of the open-field
chamber than did CX3CR1−/−-injured (TBI) mice (twoway ANOVA **p = 0.01; Fig. 2a). A modest, yet statistically
significant difference in total distance traveled was revealed between sham and TBI groups for both genotypes;
however, no difference was observed between WT-TBI
and CX3CR1−/− TBI mice. No difference was revealed between genotypes and/or injury groups in the elevated plus
maze task (data not shown).
After open-field and elevated plus maze assessments,
the same mice were also tested for coordination and
motor skill acquisition using an accelerating rota-rod during each of four trials per day on two consecutive days
(Fig. 2b). The amount of time an animal stays on the rotarod is an indicator of its general level of balance and coordination. In general, mice improve their performance
over time with training, which is an indicator of motor
learning. Sham wild-type mice performed significantly better than sham CX3CR1−/− mice, during the 2 days of
training (Fig. 2b), confirming our previous finding of
motor learning deficits in CX3CR1−/− mice [40]. No differences were observed among injury groups during the first
day of training. On the second day of training (trials 5–8),
sham WT mice remained on the rotor for longer
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Fig. 2 Evaluation of behavioral analysis 30 days post-TBI. a In the open-field task, all mice traveled the same distance in the center zone compared to
the perimeter zone. CX3CR1 WT-TBI spent less time in the perimeter zone of the open-field chamber compared to CX3CR1 KO-TBI (two-way ANOVA
(F = 3, 72, **p = 0.01). Total distance traveled in the chamber was significantly different between CX3CR1 sham WT and CX3CR1 sham KO
mice. Two-way ANOVA (F = 1, 36, **p = 0.001) and between shams and TBI groups two-way ANOVA (F = 1, 36, **p = 0.001). CX3CR1 sham WT (n = 10
white bar), CX3CR1 sham KO (n = 10 green bar), CX3CR1 WT-TBI (n = 10 red bar), and CX3CR1 KO-TBI (n = 10 blue bar) mice. b Rota-rod. CX3CR1 sham
WT mice performed significantly better than CX3CR1 sham KO mice, over the 2 days of training (repeated measures ANOVA, *p = 0.5). No difference
between injured groups was observed in the learning ability in the rota-rod task during the first day of training. On the second day of training (trials
5–8), CX3CR1 sham WT mice learned the rota-rod task as demonstrated by their ability to remain on the rod for longer periods compared to CX3CR1
WT-TBI (**p = 0.01). CX3CR1 KO-TBI mice showed a significantly worse performance than CX3CR1 WT-TBI wild-type (*p = 0.5). Neither the
CX3CR1 KO-TBI nor the CX3CR1 WT-TBI mice showed significant improvement in motor coordination with training when compared to
sham WT. CX3CR1 sham WT (n = 10; white open square). CX3CR1 WT-TBI (n = 10; red square). CX3CR1 sham KO (n = 10; green square).
CX3CR1 KO-TBI (n = 10; blue squares). c–e Morris water maze. c Mean latency to escape from a pool to a hidden platform across training
days. All groups spent more time in learning to find the platform compared to sham WT. CX3CR1 sham WT (n = 8; white bar). CX3CR1 WT-TBI (n = 9; red
square). CX3CR1 sham KO (n = 8; green square). CX3CR1 KO-TBI (n = 9; blue squares). d A probe test was performed on day 8 to determine the number of
pseudo platform crossings in the target quadrant. All TBI groups crossed less number of time the target quadrant zone when compared to CX3CR1 sham
WT. CX3CR1 KO-TBI mice crossed the target quadrant less number of time than CX3CR1 sham KO and CX3CR1 WT-TBI. e No difference was observed in
the average swim speed between groups. CX3CR1 sham WT (n = 8; white bar). CX3CR1 WT-TBI (n = 9; red square). CX3CR1 sham KO (n= 8; green square).
CX3CR1 KO-TBI (n = 9; blue squares). All data are presented as mean ± SEM p < 0.01

periods. Injured CX3CR1−/− mice performed worse
than injured WT. However, the motor impairment of
injured CX3CR1−/− mice was similar to that one observed
in sham CX3CR1−/−, likely due to the baseline (floor) effect associated with CX3CR1 deficiency. Neither injured
CX3CR1−/− mice nor injured WT mice significantly

improved motor coordination on the second day of training when compared to day 1 of training; (Fig. 2b; repeated
measures ANOVA, p < 0.0001).
Spatial learning was evaluated using the Morris water
maze (MWM) task as previously described [40]. As previously shown, the escape latency (time to find the
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platform) of sham CX3CR1−/− mice during training was
longer than that of sham WT mice (Fig. 2c). All mice
subjected to TBI, irrespective of genotype, took longer
to find the platform during training as compared to
sham WT mice. During the probe trial (day 8), the number of target platform crossings was decreased in injured
mice irrespective of genotype as compared to sham WT
mice. Injured CX3CR1−/− mice performed worse than
injured WT and sham mice (Fig. 2d). A similar trend
was observed in the time that each group spent in the
platform zone (data not shown). There was no difference
in the average swim speed among groups (Fig. 2e).
TBI-induced neuronal cell death and survival

We used Fluoro-Jade B and NeuN staining to determine
the impact of mild TBI on neuronal cell death and survival in the cortex during the transition from the acute
to chronic post-traumatic period, days 15 and 30 postTBI. Stereological analyses revealed increased numbers
of degenerating neurons (Fluoro-Jade B+ cells) in the
cortex of WT mice 15 days post-TBI as compared to
CX3CR1−/− mice (Fig. 3a; two way ANOVA, p = 0.0001;
Bonferroni post hoc p = 0.01). By 30 days post-injury,
however, the number of degenerating neurons in injured
CX3CR1−/− mice was greater than in injured WT mice
(Fig. 3, p = 0.001). Stereological quantification revealed
that the number of Fluoro-Jade B+ cells in CX3CR1−/− mice
increased from day 15 to 30 post-TBI, suggesting delayed
cell degeneration in these animals (CX3CR1−/−-TBI—15 vs
30 days, p < 0.01). Microscope visualization did not reveal
any Fluoro-Jade B+ cells in sham animals irrespective of
genotype (nd).
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Neuronal survival was determined by the stereological
quantification of NeuN+ cells (Fig. 3b). At 15 days postTBI time point, we analyzed tissue from all groups of animals (CX3CR1 sham KO, CX3CR1 sham WT, CX3CR1
KO-TBI, CX3CR1 WT-TBI). However, at 30 days, only tissue from injured TBI animals was analyzed. Neuronal cell
loss was apparent after TBI in WT mice and CX3CR1−/−
mice (Fig. 3b). In WT mice, there were fewer NeuN+ cells
15 days post-TBI than at 30 days post-TBI. In contrast,
there were more NeuN+ cells in CX3CR1−/− mice 15 days
post-TBI than at 30 days post-TBI, indicating neuronal cell
loss over time. Comparison of genotypes indicated significant differences in numbers of NeuN+ cells such that
there were more NeuN+ cells in CX3CR1−/− mice 15 days
post-TBI and more NeuN+ cells in WT mice 30 days postTBI. Collectively, these data demonstrate that CX3CR1
exacerbates cell loss during the acute phase post-TBI
(number of neurons is greater in CX3CR1−/− mice 15 days
post-TBI than in WT mice) and protects cells during the
chronic phase post-TBI (number of neurons is less in
CX3CR1−/− mice than WT mice 30 days post-TBI).
CX3CR1 deficiency correlates with increased microglial
proliferation and does not modulate the trafficking of
hematogenous myeloid cells to the brain after TBI

Because TBI involves infiltration of peripheral blood
monocytes into the brain [44], we first isolated mononuclear cells from WT and CX3CR1−/− mice at 15 or
30 days post-TBI and analyzed them with flow cytometry (Fig. 4a). Total brain mononuclear cells were counted
and compared among groups (Fig. 4b; Table 1). After
TBI in WT mice, there was an increase in overall

Fig. 3 Quantification of neuronal loss at 15 and 30 days post-TBI. Left panel (a): unbiased stereology quantification showed a significant decrease in the
number of Fluoro-Jade B+ cells in the ipsilateral cortex (F = 1, 10; *p = 0.001) of CX3CR1 KO-TBI mice (n = 3; blue bar) at 15 days post-TBI, when compared
to CX3CR1 WT-TBI (n = 3; red bar). CX3CR1 sham WT (not detected), CX3CR1 sham KO (not detected). Fifteen days post-TBI, the decrease in the number
of Fluoro-Jade B+ cells in CX3CR1 KO-TBI mice was associated with a significant increase in the number of NeuN+ cells (right pane (b); n = 3) compared
to CX3CR1 WT-TBI (n = 3 **p = 0.001). Thirty days post-TBI CX3CR1 KO mice showed increased number of Fluoro-Jade B+ cells (n = 3; *p = 0.01) which was
associated with decreased NeuN immunoreactivity (n = 5; **p = 0.001; mean ± SE (*WT vs CX3CR1−/− ± 15 vs 30 days). CX3CR1 sham WT (white bar),
CX3CR1 sham KO (green bar), CX3CR1 WT-TBI (red bar), and CX3CR1 KO-TBI (blue bar). At 30 days, the number of NeuN+ cells was not determined (nd).
Two-way ANOVA performed across genotype, treatment, and time point revealed a significant difference in the number of Fluoro-Jade and NeuN+ cells
when compared between 15 and 30 days post-injury
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Fig. 4 Increased microglial reaction after TBI. CX3CR1+/+ (WT; white bar) and CX3CR1−/− (KO, black bar) brain leukocytes were analyzed by flow
cytometry, and total cellularity, numbers of blood derived infiltrating cells, and CD45Low microglial cells were compared. a–c After TBI, a significant
increase in the overall cellularity was observed when comparing all groups at 15 days (*P < 0.05 comparing sham WT versus WT-TBI 15 days post-TBI),
and these changes were sustained 30 days post-TBI. CD45High hematogenous population did not show statistical significance among injured WT and
KO mice. d–f There was a significant increase in microglial cell number at 15 days post-TBI in WT mice when compared to sham WT group. CX3CR1
KO-TBI group also showed a significant increase in microglia number when comparing 15 and 30 days post-TBI, although effects were also seen in the
sham-treated KO group. g–i Staining for Ki67 in representative sample of WT-TBI (g upper panel) and KO-TBI (g lower panel) groups and also presented
in histogram (h) with gray line showing the isotype controls, WT-TBI Ki67 intensity in blue line, and KO-TBI in red. Data were quantified (i) revealing that
in the absence of CX3CR1, microglial cells exhibit a higher proliferative capacity (*P < 0.05)

cellularity 15 days post-TBI when compared to the
sham group (Fig. 4b, *P < 0.05). CX3CR1-KO mice
showed a slight increase in overall cellularity at 15 days
post-TBI but not statistically significant from the sham

group. However, there were no significant differences
between injured WT and CX3CR1−/− mice in the
CD45High hematogenous population (Fig. 4c), suggesting that overall the contribution of blood-derived cells
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Table 1 Total microglia cell numbers in the brain tissue. Microglia cell numbers in sham WT, sham KO, WT-TBI, and KO-TBI at 15 and
30 days post-TBI as plotted in Fig. 4b. Total microglia cell numbers in the brain tissue. Microglia cell numbers in sham WT, sham KO,
WT-TBI, and KO-TBI at 15 and 30 days post-TBI as plotted in Fig. 4f
15 days
Sham WT

30 days
Sham KO

WT-TBI

KO-TBI

Sham WT

Sham KO

WT-TBI

KO-TBI

Total cell numbers in the brain tissue after TBI (Fig. 4b)
Mean
Standard error
n

390,777

984,242

1.581 × 106

1.255 × 106

1.408 × 106

1.697 × 106

1.617 × 106

1.986 × 106

90,972

120,144

389,298

254,594

302,104

222,274

301,655

137,642

6

6

6

6

8

7

9

8

Microglia cell numbers in the brain tissue after TBI (Fig. 4f)
Mean
Standard error
n

216,305

377,880

468,937

471,776

487,667

885,237

701,797

862,206

46,031

56,377

84,401

73,242

79,322

156,709

142,253

128,469

6

6

6

6

8

7

9

8

to the inflammatory process is not altered in CX3CR1−/−
mice. Further analysis of the CD45High population was
performed using CD11b to identify all myeloid cells,
CD11c for dendritic cells (DCs), Ly6G to mark neutrophils, and CD3 to identify T cells. The results did not
reveal differences between sham and TBI groups in T cells
or infiltrating myeloid cells, including monocytes/macrophages (CD11b+CD11c−), myeloid derived DCs (CD11b
+
CD11c+), conventional DCs (CD11b−CD11c+), or neutrophils (CD11b+Ly6G+) (data not shown). Comparison of the CD45Low microglia population between
WT (Fig. 4d) and CX3CR1−/− mice (Fig. 4e) reveals a
significant increase in both groups when compared to
sham controls at 15 and 30 days post-TBI (Fig. 4f ).
Figure 4d–e shows representative plots, actual numbers
are shown on Fig. 4f; (Table 1). There is a significant effect of the sham procedure in the microglia response in
CX3CR1-KO mice that is particularly evident at day 30
and significant between the sham WT and sham KO
groups. We and others have evidence that the microglia
in these mice are more prone to activation in setting of
LPS injection, EAE, and MPTP challenge among other
models. However, TBI does have a slight effect toward
an increased number of microglia at day 30 although
not statistically significant. To assess differences in the
proliferation of the CNS-resident microglial population,
we performed flow cytometry on cells stained with the
proliferation marker Ki67 on sham controls and TBIinduced WT mice (Fig. 4g) and CX3CR1−/− mice
(Fig. 4h) 30 days after injury (Fig. 4g–i). CX3CR1−/−
mice exhibited a higher proportion of Ki67+ microglia
(Fig. 4i) irrespective of injury. This result highlights the
importance of CX3CR1 in controlling microglial proliferation even under conditions of skull exposure without CCI
because microglial proliferation in naïve (unmanipulated)
CX3CR1−/− mice is similar to that of WT mice [43].
Collectively, these results suggest that CX3CR1 plays an

important role in inhibiting the microglia reaction in this
model of TBI.
Impact of mild TBI on microglia phenotypes

To determine whether the protective and neurotoxic effects of CX3CR1 signaling following mild TBI were due
to activation of different microglia phenotypes, we quantified microglia immunoreactivity in cortical sections obtained from mice 15 and 30 days post-TBI. We first
analyzed CD11b, a marker common to all microglia phenotypes, and found there were more CD11b+ cells in
CX3CR1−/− mice than in WT mice 15 days post-TBI. By
30 days post-TBI, the number of CD11b+ cells increased
to the same extent in WT and in CX3CR1−/− mice (Fig. 5
a, b). We performed immunostaining for both sham
groups, CX3CR1 KO and WT. CD11b staining intensity
showed similar intensity in the cortex of KO and sham
WT animals, and it appeared to be lower compared to
TBI groups. Therefore, we did not perform stereological
analysis for sham animals.
Then, we immunostained cortical tissues for markers
associated with M2 microglial and M1 microglial activation phenotype and at 7, 15, and 30 days post-TBI (YM1
chitinase 3-like 3; CD206 mannose receptor; CD68
Marco). At 7 days post-TBI, the expression of the M2a
markers YM1 and CD206 increased in the cortex of
brain-injured CX3CR1−/− mice, but not brain-injured WT
mice (Fig. 6a–h showing M2 expression in the cortex).
YM1 and CD206 were not detected in the brains of sham
animals of either genotype (Fig. 6d, h). No M2 markers
were detected at 15 or 30 days post-TBI. We then used
qRT-PCR to determine M2-TGFβ-associated gene expression at 7 days post-TBI. Sham CX3CR1−/− mice had decreased TGFβ mRNA levels (p < 0.001) compared to sham
WT mice (Fig. 6i). Seven days post-TBI, TGFβ mRNA significantly increased in injured CX3CR1−/− mice as compared to sham CX3CR1−/− (p < 0.001). No difference was
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Fig. 5 Stereological quantification of CD11B+ cells in the cortex at 15 and 30 days post-injury. a ×10 magnification micrographs of CD11B staining in the
cortex in the vicinity of the lesion. Upper panel shows the staining’s intensity in CX3CR1 sham WT and CX3CR1 WT-TBI at 15 and 30 days post-injury. Lower
panels show the staining’s intensity in CX3CR1 sham KO and CX3CR1 KO-TBI at 15 and 30 days post-injury. b The cortical expression of CD11b+ cells was
significantly increased in CX3CR1 KO-TBI (n = 6) mice compared to CX3CR1 WT-TBI mice (n = 5) at 15 days post-TBI (*p = 0.05). Two-way ANOVA revealed
that the number of CD11b+ cells increased in the cortex from day 15–30 post-TBI to the same extent in CX3CR1 WT-TBI and in CX3CR1 KO-TBI
mice (±±p = 0.001). Staining in sham animals was not determined (nd). CX3CR1 sham WT (white bar), CX3CR1 sham KO (green bar), CX3CR1
WT-TBI (red bar), CX3CR1 KO-TBI (blue bar)

observed between injured CX3CR1−/− and injured WT
mice. We also analyzed gene expression of iNOS and IL1β at 7 days post-TBI. Levels of mRNA for iNOS and IL-1
were significantly greater in sham CX3CR1−/− mice than
sham WT mice (Fig. 6i, p < 0.001). In contrast, iNOS and
IL-1 significantly decreased in injured CX3CR1−/− mice
compared to injured WT mice. Furthermore, iNOS and
IL-1 mRNA levels in injured CX3CR1−/− mice were significantly decreased compared to sham CX3CR1−/− mice
(see Table 2). Finally, we analyzed M1 and M2-associated
protein expression of IL-1β, IL-6, and IL-4, respectively, in
CX3CR1−/− and WT mice at 15 days post-TBI. Figure 7
shows that IL-1 and IL-6 increased in WT mice subjected
to TBI, whereas IL-4 increased in CX3CR1−/− mice. M1
marker Marco was analyzed at 30 days post-TBI, and M1
marker CD68 was analyzed at 15 and 30 days post-TBI
(Fig. 8). The time course and anatomical expression of
Marco was different between WT and CX3CR1−/−. In WT
mice, Marco was expressed in the hippocampus (but not
in the cortex) at 7, 15, and 30 days post-TBI, while in
CX3CR1−/− mice, Marco expression was only evident
at 30 days post-TBI; thus we only quantified Marco
at 30 days in hippocampus. Thirty days post-TBI,
Marco was highly expressed in injured CX3CR1−/−
mice (Fig. 8a–c). CD68, a specific marker of phagocytic microglia, was decreased at 15 days post-TBI in
CX3CR1−/− mice relative to WT mice, but by 30 days
post-injury, there were no significant differences between genotypes (Fig. 8d, e).

Discussion
Results of this study demonstrate for the first time that
CX3CR1 modulates responses to mild TBI in a timedependent manner. During the acute post-traumatic
period (24 h–15 days), neuronal cell loss is greater in the
brain-injured WT than in the brain-injured CX3CR1−/−
mice. In contrast, during the chronic phase (30 days
post-injury), lack of CX3CR1 exacerbates neuronal damage. The acute post-TBI phase in CX3CR1−/− mice is associated with a protective M2 microglia phenotype as
evidenced by upregulation of YM1 and CD206 and
increased TGFβ, IL-4, and IL-10. Concurrently with the
M2 microglia phenotype during this acute post-traumatic
period, responses of CX3CR1−/− mice to TBI include a reduction in M1 microglia phenotype markers, such as iNOS
and IL-1β. During the chronic post-injury phase, the brains
of injured CX3CR1−/− mice show a profound inflammatory
response compared to brains of injured WT mice. This
post-traumatic chronic response in mice lacking CX3CR1
is characterized by an inflammatory M1 microglia phenotype, as evidenced by upregulation of Marco, CD68, and
the inflammatory cytokines IL-1β and IL-6.
One interpretation for the decrease in TGFβ and IL-4 in
the sham KO mice is that lack of CX3CR1 leads to a
decrease in the M2-type responses in favor of M1-type
responses (increased IL-1β). However, future work will be
necessary to test this interpretation and to determine if
the polarization of M1-type over M2 type responses is cell
autonomous or involves a paracrine signaling mechanism.
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Fig. 6 Immunostaining, stereological quantification, and qPCR analysis of M2 and M1 polarization markers in cortex at 7 days post-TBI. a–d YM1
shows a strong increase in staining in the CX3CR1 KO-TBI compared to CX3CR1 WT-TBI at 7 days post-injury. a Micrograph at ×4 magnification
showing YM1 staining in the proximity of the lesion area in CX3CR1 KO-TBI mice. b Higher magnification (×10) of the area indicated by the red
arrow in (a). c Higher magnification (×20) of the area in the proximity of the lesion of CX3CR1 WT-TBI and CX3CR1 KO-TBI showing in more detail
microglial YM1 morphology. d Unbiased stereology revealed a significant increase in the number of YM1 and CD2O6+ cells (right panel) in the
cortex of CX3CR1 KO-TBI mice (n = 3) compared to CX3CR1 WT-TBI (n = 4). e–h CD206 shows a strong increase in staining in the CX3CR1 KO-TBI
compared to CX3CR1 WT-TBI at 7 days post-injury. e Micrograph at ×4 magnification showing CD206 staining in the proximity of the lesion area
in CX3CR1 KO-TBI mice. f Higher magnification (×10) of the area indicated by the red arrow in (a). g Higher magnification (×20) of the area in the
proximity of the lesion of CX3CR1 WT-TBI and CX3CR1 KO-TBI showing in more detail microglial CD206 morphology. h Unbiased stereology revealed a
significant increase in the number of CD2O6+ cells in the cortex of CX3CR1 KO-TBI mice compared to CX3CR1 WT-TBI. YM1 and CD206
were not detected in sham mice (**p < 0.001). i Relative mRNA levels of M2 marker TGFβ were significantly lower in sham CX3CR1 sham
KO (n = 5) compared to CX3CR1 sham WT (n = 5). Following TBI, the expression of TGFβ significantly increased in CX3CR1 KO mice compared to sham
(n = 5; **p < 0.001) but was not different compared to CX3CR1 WT-TBI (n = 5). M1 markers iNOS (middle panel) and IL-1β (right panel) were similar in
the cortex of CX3CR1 sham KO (n = 5) compared to CX3CR1 sham WT (n = 5). Following injury, iNOS and IL-1β mRNA levels in CX3CR1 KO-TBI (n = 5)
were significantly decreased compared to CX3CR1 WT-TBI (n = 5). **p < 0.001). CX3CR1 sham WT (white bar), CX3CR1 sham KO (green bar),
CX3CR1 WT-TBI (red bar), and CX3CR1 KO-TBI (blue bar)
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Table 2 CT, ΔCT, and fold change. TGFβ, iNOS, and IL-1β raw
numbers as plotted in Fig. 6g. Numbers are expressed as CT, ΔCT,
and fold change (means and standard deviations) normalized
against wild-type sham
Treatment Genotype Gene CT
(mean ± SD)
Sham

TBI

Sham

TBI

Sham

TBI

ΔCT
(mean ± SD)

Fold change
(mean ± SD)

WT

TGFβ 25.368 ± 0.31 12.429 ± 0.31 1.000 ± 0.20

KO

25.751 ± 0.23 12.775 ± 0.26 0.782 ± 0.14

WT

25.268 ± 0.03 12.255 ± 0.11 1.107 ± 0.08

KO

25.451 ± 0.32 12.451 ± 0.33 1.154 ± 0.06

WT

iNOS 29.156 ± 0.11 16.558 ± 0.11 1.000 ± 0.07

KO

29.037 ± 0.12 16.450 ± 0.14 1.080 ± 0.11

WT

28.802 ± 0.24 16.335 ± 0.29 1.187 ± 0.13

KO

29.168 ± 0.06 16.654 ± 0.08 0.933 ± 0.09

WT

IL-1β 28.340 ± 1.01 16.747 ± 099

1.000 ± 0.60

KO

29.705 ± 1.73 17.109 ± 1.72 1.521 ± 0.17

WT

28.903 ± 0.93 16.435 ± 0.90 1.191 ± 0.57

KO

29.259 ± 0.80 16.715 ± 0.80 0.968 ± 0.51

The predominant M1 response in injured CX3CR1−/−
brain is associated with poorer performance in the Morris water maze. We previously demonstrated that lack of
CX3CR1 impairs motor and cognitive function [40]. We
now show that lack of CX3CR1 during the chronic
phase of mild brain injury exacerbates this already impaired cognitive function. However, it is important to
take in consideration that both RT-PCR and ELISA data
have been obtained from whole brain tissue, not from
extracted microglia; therefore, we cannot determine with
absolute certainty the cellular source of these signals.
Furthermore, it has to be noted that although the statistical analysis indicated significant difference between
CX3CR1 WT-TBI and CX3CR1 KO-TBI in mRNA levels
for TGFβ, iNOS, and IL1, the physiological significance
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of such changes may be questionable and bigger changes
may be observed at earlier time points.
Collectively, these observations demonstrate that
CX3CR1 is both neuroprotective and neurotoxic in
brain injury depending on the time post-injury. Importantly, these findings suggest that antagonizing the
CX3CL1/CX3CR1 pathway during a critical period
after mild TBI may reprogram the brain inflammatory
environment from detrimental to beneficial, favoring
endogenous neuroprotective or neurorestorative mechanisms. Furthermore, results from this study provide
important new knowledge that is relevant to the differential roles of the CX3CL1/CX3CR1 pathway that have
been described in a number of pathologies.
Our findings are in agreement with several reports
demonstrating in other models that CX3CR1 drives inflammatory responses during the acute period following
CNS injury. For instance, in focal cerebral ischemia,
Dénes et al. [24] reported reduced damage to the bloodbrain barrier, which correlated with a protected phenotype, reduced ischemic volume, fewer apoptotic cells,
and better performance in the behavioral test of adhesive
tape removal. Similarly, CX3CR1−/− mice are protected
from the middle cerebral artery occlusion, with smaller
infarct size at early time points after injury, which is associated with an M2 microglial phenotype [26]. In a
model of spinal cord injury, CX3CR1−/− mice had more
favorable outcome 5 days post-injury, with neuroprotection and functional recovery, than WT control mice
[23]. The improved recovery after traumatic spinal cord
injury is associated with reduced recruitment of monocytes/macrophages to the site of injury. Collectively,
these studies underscore a role for CX3CR1 signaling in
response to CNS injury and suggest that mechanisms by
which CX3CR1 promotes neuroprotection during the acute
phase of brain injury include a protective microglia phenotype and reduced monocyte/macrophage recruitment.

Fig. 7 a–c Fifteen days post-injury, CX3CR1 WT mice show increased protein levels of IL-1 (a), IL-6 (b), and decreased levels of IL-4 (c). CX3CR1
KO-TBI mice show increased IL-4 protein levels. CX3CR1 sham WT (white bar), CX3CR1 sham KO (green bar), CX3CR1 WT-TBI (red bar), and CX3CR1
KO-TBI (blue bar) (*P < 0.05)
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Fig. 8 Immunostaining and stereological quantification for M1 polarization markers in hippocampus at 30 days post-TBI. a Micrograph at ×4 magnification
showing Marco staining at 30 days post-TBI in the dentate gyrus of CX3CR1 WT-TBI and CX3CR1 KO-TBI mice. b Higher magnification (×20) of the dentate
gyrus of CX3CR1 WT-TBI and CX3CR1 KO-TBI showing in the hippocampus show a strong increase in staining in the CX3CR1 KO-TBI compared to CX3CR1
WT-TBI at 30 days. c Unbiased stereology quantification of Marco revealed a significant increase in the number of Marco+ cells in the hippocampus of
CX3CR1 KO-TBI compared to CX3CR1 WT-TBI (p < 0.001). d Micrograph at ×20 magnification of the dentate gyrus of CX3CR1 WT-TBI and CX3CR1 KO-TBI
showing in the hippocampus show a strong increase in CD68 staining in the CX3CR1 KO-TBI compared to CX3CR1 WT-TBI at 30 days post-TBI. e Time
course of CD68 expression at 15 and 30 days post-injury. Stereological quantification of CD68+ cells revealed a significant decrease in CX3CR1 KO-TBI mice
compared to CX3CR1 WT-TBI at 15 days post-TBI. Although the difference did not reach statistical significance, at 30 days post-TBI, expression of CD68 was
higher in CX3CR1 KO-TBI mice compared to wild-type (**p < 0.001)
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Our data indicate that CD68, a specific marker of
phagocytic microglia, is decreased at 15 days posttrauma in CX3CR1−/− mice and, in this present study,
tends to increase by 30 days post-injury. Although
microglial phagocytosis of dead or dying neurons can be
beneficial by preventing the release of pro-inflammatory
molecules, under some conditions, such as inflammation, microglia also phagocytize viable neurons, thus
contributing to cell death [45]. Intraventricular infusion
of mesenchymal stem cells after TBI induces early and
lasting acquisition of a protective M2 microglial phenotype that is associated with reduced CD68 immunoreactivity [46]. Based on these observations, we hypothesize
that the reduced phagocytic activity in CX3CR1−/− mice
could be beneficial to neurons and perhaps explain neuroprotection at 15 days post-trauma on these animals.
On the other hand, increased phagocytosis 30 days postTBI could be detrimental and increase neuronal death.
However, CD68 immunoreactivity may not necessarily
correlate with phagocytosis [47, 48]. For example, microglia that are phagocytizing apoptotic cells in physiological conditions in the hippocampus do not express
CD68 [47, 48]. Experiments to specifically address this
issue remain to be conducted. Nevertheless, our data
show that a transient protective M2 microglia phenotype
with decreased CD68 phagocytic activity manifests early
after mild TBI in CX3CR1−/− mice.
The dramatic shift during the chronic phase of brain injury in CX3CR1−/− mice limits the recruitment of M2
microglia and switches the balance toward the M1 phenotype, which contributes to excessive inflammatory responses and exacerbated neuronal damage. Although a
shift in microglia phenotype between the acute and
chronic phase of TBI has recently been reported [49], we
extend these observations by identifying CX3CR1 as a
possible regulator of this microglia/macrophage phenotype switch following mild TBI. It is important to note
however, that the transition between M1 and M2 microglia phenotypes is not all or none, and several intermediate microglia phenotypes with overlapping features have
been described during the shift between alternatively
activated phenotypes. Indeed, recently Morganti et al.
[50] using CX3CR1GFP/+ CCR2RFP/+ reporter mice have
demonstrated a broad spectrum of M1-M2 polarization
mRNA gene expression following TBI, with changes
occurring primarily during the first 48 h. Importantly,
they reported that there was not a clear delineation
of an exclusive M1, M2a, or M2c phenotype. Several
factors could explain differences between our study
and that of Morganti et al.; ours is a model of mild
TBI model, and our M1 and M2 analysis was based
on both gene expression and immunohistochemical
assessment, whereas the Morganti study only reported
on gene expression.
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Although our data do not provide information as to
precisely how CX3CR1 dictates the recruitment of M1/
M2 microglia during acute or chronic stages of the disease, there likely are multiple mechanisms that regulate
the neuroprotective vs. neurotoxic effects of microglia
after mild TBI. Relative expression of CX3CR1 defines
two phenotypically distinct monocyte subsets. Monocytes of the Ly6Chigh/CX3CR1low subset express CCR2, a
chemokine receptor that facilitates recruitment of inflammatory monocytes to the site of injury. Conversely,
monocytes of the subset Ly6Clow/CX3CR1high are CCR2
deficient and are dependent on CX3CR1 for recruitment
[51–53]. CX3CR1+ monocytes may differentiate from
Ly6Chigh monocytes in tissue and thus may not require
CX3CR1 for recruitment [54, 55]. These distinct monocyte populations are associated with tissue pathology
and repair. For example, in a model of myocardial infarction, tissue repair requires recruitment of Ly6Chigh
and then Ly6Clow monocytes [53]. Ly6Chigh monocytes
are proteolitic, degrade injured tissue, and give rise to
M1 macrophages in vivo [35, 56]. Other reports demonstrate that the Ly6Clow/CX3CR1high monocyte subset is
associated with beneficial effects as this population is
capable of tissue healing [53].
In experimental models of spinal cord injury and focal
cerebral ischemia, tissue damage is attenuated and function recovers earlier following injury in CX3CR1-deficient
mice, effects attributed to reduced recruitment and/or
activation of microglia/macrophages [23, 24, 57, 58]. Inhibiting CX3CR1 at early time points in a model of ischemic
brain injury protects neurological function and reduces
neuropathology by decreasing CD11b+/Ly6Clow/iNOS+
monocyte recruitment, microglia proliferation, and
leukocyte infiltration [58]. Similarly, Donnelly et al. [23]
showed that abolishing CX3CR1 reduces accumulation of
CD11b+/Ly6Clow/iNOS+ monocytes, which confers neuroprotection and promotes recovery of function at early
time points after spinal cord injury. These benefits are associated with suppressed inflammatory signaling in microglia and microglia-derived macrophages.
In our model of mild focal TBI, we did not detect differences in leukocyte infiltration from the periphery between wild-type and CX3CR1-deficient mice. Lack of
differences between CX3CR1-deficient and wild-type
mice could be due to the post-TBI time point analyzed
and/or the mild TBI induced in this study. However,
based on these aforementioned observations and our
data, we hypothesize that after focal TBI, CX3CR1 plays
a fundamental role in dictating the timing of recruitment
of inflammatory monocyte populations relative to the
protective monocyte populations, which results in a detrimental and protective microglia phenotype, respectively. Our results may reconcile data obtained from a
number of pathologies with respect to whether CX3CR1
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is protective or neurotoxic. Taken together, our data suggest that CX3CR1 may be an ideal target for therapeutic
intervention in the acute post-traumatic period to delay
secondary brain damage.
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